Nabaxor (Rivaroxaban)

Rivaroxaban acts on the coagulation cascade to reduce thrombus formation in several venous and arterial conditions.

• Non‑valvular atrial fibrillation: prevents stroke and systemic embolism.
• Deep vein thrombosis (DVT): treats acute clot formation.
• Pulmonary embolism (PE): treats acute clot formation and reduces recurrence risk.

• Rivaroxaban selectively and reversibly inhibits factor Xa, a key enzyme in the conversion of prothrombin to thrombin. By blocking this step, it reduces thrombin generation and fibrin clot formation, thereby providing anticoagulant activity without requiring antithrombin as a cofactor.

Rivaroxaban may cause bleeding‑related reactions and other adverse events.

Common Side Effects

• Bruising: mild to moderate skin discoloration at sites of minor trauma.
• Nosebleeds: occasional epistaxis without severe sequelae.
• Headache: transient mild to moderate intensity.
• Gastrointestinal upset: nausea or diarrhea.

Serious or Rare Side Effects

• Intracranial hemorrhage: life‑threatening bleeding within the skull.
• Spinal or epidural hematoma: bleeding that may cause spinal cord compression.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Liver injury: abnormal hepatic enzymes or hepatitis.

Before initiating rivaroxaban therapy, consider patient‑specific risk factors and monitor appropriately.

• Renal impairment: assess kidney function and adjust therapy as directed.
• Hepatic disease: use with caution in patients with active liver disease.
• Concomitant antiplatelet agents: increased risk of bleeding, monitor closely.
• Surgery or invasive procedures: discontinue according to clinical guidelines to reduce bleeding risk.
• Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Rivaroxaban interacts with several drug classes that may alter its anticoagulant effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Other anticoagulants (e.g., warfarin, heparin): additive bleeding risk.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs, e.g., ibuprofen): increased gastrointestinal bleeding risk.
• Selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine): potential for enhanced bleeding.